Allergan (AGN) Given Average Rating of “Buy” by Brokerages

Shares of Allergan (NYSE:AGN) have been assigned a consensus rating of “Buy” from the twenty-seven brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and fifteen have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $216.74.

AGN has been the subject of several research reports. Citigroup reiterated a “buy” rating and issued a $200.00 target price (down previously from $220.00) on shares of Allergan in a research note on Tuesday. Evercore ISI initiated coverage on shares of Allergan in a research note on Monday. They issued an “outperform” rating for the company. Credit Suisse Group set a $215.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Sunday. Stifel Nicolaus initiated coverage on shares of Allergan in a research note on Tuesday, April 17th. They issued a “hold” rating and a $192.00 target price for the company. Finally, Vetr cut shares of Allergan from a “buy” rating to a “hold” rating and set a $171.99 target price for the company. in a research note on Tuesday, April 17th.

How to Become a New Pot Stock Millionaire

AGN stock traded down $2.99 during mid-day trading on Thursday, reaching $156.90. 2,351,839 shares of the stock traded hands, compared to its average volume of 3,210,291. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 1.06. Allergan has a 52 week low of $142.81 and a 52 week high of $256.80. The stock has a market capitalization of $55,215.16, a price-to-earnings ratio of 9.60, a price-to-earnings-growth ratio of 1.13 and a beta of 1.17.

Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The company had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period in the prior year, the company earned $3.90 earnings per share. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. equities analysts expect that Allergan will post 15.59 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.84%. The ex-dividend date of this dividend was Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is 17.61%.

In other news, insider Maria Teresa Hilado acquired 895 shares of the company’s stock in a transaction dated Thursday, March 15th. The stock was bought at an average price of $167.39 per share, with a total value of $149,814.05. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 58,879 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 8,095 shares of company stock valued at $1,258,081. Company insiders own 0.37% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Avestar Capital LLC acquired a new stake in shares of Allergan in the fourth quarter valued at approximately $113,000. Focused Wealth Management Inc increased its holdings in shares of Allergan by 4,444.4% in the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after purchasing an additional 800 shares in the last quarter. Acropolis Investment Management LLC acquired a new stake in shares of Allergan in the fourth quarter valued at approximately $153,000. Field & Main Bank acquired a new stake in shares of Allergan in the fourth quarter valued at approximately $155,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Allergan in the fourth quarter valued at approximately $175,000. 78.35% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at

About Allergan

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.

Leave a Reply